News

October 1, 2009 – Invatec recently launched the REEF HP PTA Balloon Catheter at CIRSE 2009, which the company said is ideal for use in all peripheral high-pressure dilatation procedures.

Home October 01, 2009
Home
News

October 1, 2009 – Spectranetics Corp. yesterday said it filed a 510(k) application with the U.S. Food and Drug Administration seeking clearance for the treatment of in-stent restenosis (ISR) in the legs with its commercially available peripheral atherectomy laser products.

Home October 01, 2009
Home
News

September 30, 2009 – PLC Systems Inc. demonstrated its RenalGuard System to help prevent contrast-induced nephropathy (CIN) and presented data from its MYTHOS Clinical Trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 symposium last week in San Francisco.

Home September 30, 2009
Home
News

September 30, 2009 – Invatec this week at the European CIRSE 2009 conference launched its latest self-expanding peripheral stent system, Maris Plus, which has a “lesion-specific” design with larger sizes to meet the clinical requirements of the iliac region.

Home September 30, 2009
Home
News

September 30, 2009 – New clinical data released at TCT 2009 last week showed strong and sustained efficacy and safety of the Resolute Zotarolimus-Eluting Coronary Stent from Medtronic Inc. in long-term patient follow-up.

Home September 30, 2009
Home
News

September 30, 2009 - A new study published in the Society for Vascular Surgery's October 2009 issue of the Journal of Vascular Surgery reports that the elderly have better operative outcomes when endovascular repair, rather than open surgery, is used to treat an abdominal aortic aneurysm (AAA).

Home September 30, 2009
Home
News

September 30, 2009 – A simple, noninvasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

Home September 30, 2009
Home
bbott's XIENCE V Everolimus-Eluting Coronary Stent achieved superiority in the key safety and efficacy measures compared to the TAXUS Express Paclitaxel-Eluting Coronary Stent at one year in SPIRIT IV Trial.
Feature | Stents | Dave Fornell

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent achieved superiority in the key safety and efficacy measures compared to the TAXUS Express Paclitaxel-Eluting Coronary Stent at one year, which will likely guarantee XIENCE’s continued domination of t

Home September 30, 2009
Home
News

September 30, 2009 – MAQUET Cardiovascular said Johannes Bonatti, M.D., professor of surgery and director of coronary surgery and advanced coronary interventions at the University of Maryland Heart Center in Baltimore, recently completed the world's first use of the MAQUET Minimized Extra-Corporeal Circulation (MECC) system during a successful robotic and fully endoscopic heart surgery.

Home September 29, 2009
Home
News

September 30, 2009 – Positron Corp. predicts a significant rise in demand for cardiac PET in 2010 with a proposed cut in SPECT reimbursement of 46 percent and an increase in PET reimbursement of 22 percent, issued by the Centers for Medicare & Medicaid Services (CMS).

Home September 29, 2009
Home
News

September 29, 2009 – Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve several pending lawsuits over intellectual property related to drug-eluting stent and balloon deliver system technologies.

Home September 29, 2009
Home
News

September 29, 2009 – Abiomed Inc. announced new clinical data last week at TCT 2009 from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.

Home September 29, 2009
Home
News

September 29, 2009 – Volcano Corp.

Home September 29, 2009
Home
News

September 29, 2009 – Mardil Inc. last week at TCT 2009 announced positive interim data from a pilot study investigating the safety and efficacy of its novel cardiac device – BACE (Basal Annuloplasty of the Cardia Externally) – in treating mitral valve regurgitation.

Home September 29, 2009
Home
News

September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus and myolimus-eluting coronary stent systems with durable and bioabsorbable polymers. Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer

Home September 29, 2009
Home
Subscribe Now